Media.Player

Novel Chitosan Derivative as a Systemic Drug Delivery Agent and an Antibiotic Treatment

技術應用

This chitosan derivative may be used to deliver prokaryotic gene silencing CRISPR RNA as a possible treatment for drug resistant infections. Upon acidification, the native chitosan is released. This native chitosan may then damage the bacterial cell membrane and/or interrupt bacterial biological processes by stimulating reactive oxidative species generation. This chitosan/siRNA complex may deliver a one-two punch to combat drug resistant infections.

詳細技術說明

Proposed uses of chitosan now under research include drug delivery and currently it is used as a topical antibiotic in bandages. However chitosan is a highly insoluble material. Researchers at UCI have modified chitosan with a few hydrophilic functional groups so that the chitosan derivative is more water soluble. This novel chitosan derivative may be used as a systemic drug delivery agent and/or an oral or intravenous antibiotic. Novel siRNAs or other nucleic acids may be complexed with this novel derivative chitosan so the complex may be delivered as a drug therapy to a patient. Upon acidic conditions, the nucleic acid is freed from the complex and the derivative chitosan is hydrolyzed thus releasing chitosan which may act as an antibiotic therapy.

*Abstract

Researchers at the University of California, Irvine have developed a novel chitosan derivative that may be used simultaneously as a systemic drug delivery agent and a systemic antibiotic treatment.

*IP Issue Date

Feb 13, 2018

*Principal Investigation

Name: Julius Edson

Department:

Name: Young Jik Kwon

Department:

申請號碼

9889204

其他

Testing

This chitosan derivative has been tested for its efficiency as a delivery vehicle for pGFP in HeLa cells.

Tech ID/UC Case

24412/2015-035-0

Related Cases

2015-035-0

國家/地區

美國